mass spectrometry raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-10-20 and is reviewed periodically as new material appears.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV; not a natural hormone. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Naming conventions differ across vendors and papers. |
| CAS Registry Number | 1401708-83-6 | Listed in some chemical databases; verify against primary sources. |
| Appearance | White to off-white powder | Typical form for lyophilized research peptides. |
| Solubility | Soluble in DMSO; limited in water | Organic stock solutions are common in laboratory settings. |
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Purity and identity are usually assessed with reverse-phase high-performance liquid chromatography (RP-HPLC) and mass spectrometry. RP-HPLC separates components by hydrophobicity and can estimate peptide purity. Mass spectrometry confirms molecular mass and helps detect truncations or modifications. Some laboratories also use amino acid analysis or nuclear magnetic resonance for structural verification. A certificate of analysis from a supplier may list these results, but independent verification is often recommended for critical work.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
== Metabolism == It is formed from L-histidine through the action of histidine ammonialyase (also known as histidase or histidinase) by elimination of ammonium. In the liver, urocanic acid is transformed by urocanate hydratase (or urocanase) to 4-imidazolone-5-propionic acid and subsequently to glutamic acid.
The Golden Dome is a planned multi-layer missile defense system for the United States, intended to detect and destroy ballistic, hypersonic, and cruise missiles before they launch or during their flight. On January 27, 2025, President Donald Trump signed an executive order directing the secretary of defense to submit a plan for the Iron Dome for America system, which was later renamed Golden Dome. It extends former programs such as Prompt Global Strike, the Proliferated Warfighter Space Architecture, and the Strategic Defense Initiative. The initial name alluded to Israel's short-range Iron Dome system, but the Golden Dome would encompass the entire Earth, more like the Strategic Defense Initiative proposed by President Ronald Reagan in 1983. The system would employ a constellation of thousands of satellites equipped with sensors and interceptors that would be the first U.S. space weapons in orbit. Data centers in space would provide automated command and control through a cross-domain artificial intelligence-enabled network. Interceptors would fly in rapid orbit just outside the atmosphere, with only a small fraction available at the right time and place to act on any given threat—a flaw that critics argue makes the concept less efficient than traditional regional missile defenses such as the Iron Dome. In 2019, Donald Trump said the satellites would also carry offensive weapons.
Malonylation occurs mainly in mitochondria but also in the cytosol and nucleus. In mouse liver, about 60% of malonylated proteins are mitochondrial, whereas in human fibroblasts the distribution is more even. Succinylation and glutarylation are likewise enriched in mitochondria but not exclusive to them. The relative abundance of these modifications reflects acyl-CoA availability: acetylation is most common, succinylation reaches 10–30 % of acetylation levels, malonylation is at least tenfold less frequent, and glutarylation occurs only in trace amounts. In addition to their differing frequencies, malonylation, succinylation, and acetylation can also target the same lysine site. In mouse liver mitochondria, about 85 % of succinylation sites overlap with at least one of these modifications, and ~6 % can contain all three, mainly in proteins involved in fatty acid oxidation, glutaryl-CoA degradation, and ketogenesis. In contrast, only 55 % of malonylation sites overlap with succinylation, while about 45 % are unique. These distinct patterns suggest a specific regulatory role for malonylation among lysine acyl modifications.
=== Major depressive disorder === The mechanistic rationale for KOR antagonism in major depressive disorder (MDD) derives from the observation that chronic stress and depression are associated with higher activity of the KOR system. KOR activation suppresses dopamine release and prevents dopamine rebound after stress exposure, thereby leading to anhedonia and depressive phenotypes. KOR antagonists reverse this pathway by disinhibiting dopaminergic tone and restoring reward sensitivity. KOR-mediated upregulation of pro-inflammatory signaling in microglia likely drives the depression pathophysiology, and antagonism may provide benefits. The claustrum-prelimbic cortex circuit operates via dynorphin and KOR signaling to modulate cognitive and affective functions. Buprenorphine/samidorphan (ALKS-5461) displayed antidepressant efficacy in randomized controlled trials as an adjunctive therapy and has shown durable effects with a favorable safety profile including low abuse potential and minimal withdrawal symptoms. A phase 2 study demonstrated significant reduction of depressive symptoms and improvement in anhedonia when aticaprant was added to existing antidepressant therapy. A phase 3 clinical trials (KOASTAL-1 and additional studies) of navacaprant failed to achieve statistically significant superiority over placebo across the broader MDD population, with its development discontinued for this purpose in early 2025.
== History == ACAM2000 is a vaccine developed by Acambis, which was acquired by Sanofi Pasteur in 2008, before selling the smallpox vaccine to Emergent Biosolutions in 2017. Six strains of vaccinia were isolated from 3,000 doses of Dryvax and found to exhibit significant variation in virulence. The strain with the most similar virulence to the overall Dryvax mixture was selected and grown in MRC-5 cells to make the ACAM1000 vaccine. After a successful Phase I trial of ACAM1000, the virus was passaged three times in Vero cells to develop ACAM2000, which entered mass production at Baxter. The United States ordered over 200 million doses of ACAM2000 in 1999–2001 for its stockpile, and production is ongoing to replace expired vaccine. Emergent Biosolutions developed ACAM2000 under a contract with the US Centers for Disease Control and Prevention (CDC). The US Food and Drug Administration (FDA) approved ACAM2000 in August 2007. By February 2008, it replaced Dryvax for all smallpox vaccinations. As of 2010, there were over 200 million doses manufactured for the US Strategic National Stockpile. According to the US FDA, "The approval and availability of this second-generation smallpox vaccine in the Strategic National Stockpile (SNS) enhances the emergency preparedness of the United States against the use of smallpox as a dangerous biological weapon." In August 2024, ACAM2000 was approved for mpox prevention in the United States.
Sources: en.wikipedia.org
=== Immunotherapy for cancer === According to Helen Nauts from Cancer Research Institute, on a monograph reviewing the effects of bacterial infections on multiple types of cancer, Ivan Bogdanov, a Bulgarian physician, allegedly produced a vaccine consisting of lactobacillus bulgaricus and used it to treat two patients with myeloma, inducing remission in the two cases, one dying 18 months later due to influenza, and another living 45 months (survival median at the time was about 12–18 months). However, references are internal documents and conversations among hospitals; there's no mention in English medical literature. An article from a commercial site and an alleged documentary are available (in Bulgarian).
Algae are used as foods in many countries: China consumes more than 70 species, including fat choy, a cyanobacterium considered a vegetable; Japan, over 20 species such as nori and aonori; Ireland, dulse; Chile, cochayuyo. Laver is used to make laverbread in Wales, where it is known as bara lawr. In Korea, green laver is used to make gim. Some of the most commonly used microalgae as food are:
Motilin is a 22-amino acid polypeptide hormone in the motilin family that, in humans, is encoded by the MLN gene. Motilin is secreted by endocrine Mo cells (also referred to as M cells, which are not the same as the M cells, or microfold cells, found in Peyer's patches) that are numerous in crypts of the small intestine, especially in the duodenum and jejunum. It is released into the general circulation in humans at about 100-min intervals during the inter-digestive state and is the most important factor in controlling the inter-digestive migrating contractions; and it also stimulates endogenous release of the endocrine pancreas. Based on amino acid sequence, motilin is unrelated to other hormones. Because of its ability to stimulate gastric activity, it was named "motilin." Apart from in humans, the motilin receptor has been identified in the gastrointestinal tracts of pigs, rats, cows, and cats, and in the central nervous system of rabbits.
=== Drug delivery === The structure of aquasomes enables dual drug delivery, or the delivery of two drugs simultaneously. This practice aims to enhance the therapeutic efficiency and reduce the side effects of the drugs delivered. Such systems can be useful in treating patients suffering from multiple diseases. Challenges in dual drug delivery include independently controlling release rates of each of the drugs loaded in the system. In a 2019 study by Damera et al., aquasomes were used to deliver bovine serum albumin (BSA) in combination with one of three therapeutic drugs (Coumarin 153, Warfarin, and Ibuprofen), allowing release of a bioactive molecule and a hydrophobic drug simultaneously. Damera et al. suggested that dual drug delivery was enabled by the bioactive molecule layer of the aquasome being BSA. This BSA layer interacted with the hydrophobic therapeutic drugs, and the strength of the binding interactions was shown to affect the release behaviors of the drugs. Dual drug delivery with aquasomes thus shows promise for treatment of patients with coexisting diseases alongside hypoalbuminemia, as the albumin from BSA can treat the hypoalbuminemia while the additional drug treats the disease.
=== Oceania === 14UD The Australian National University, Canberra, Australia SSAMS The Australian National University, Canberra, Australia ANTARES 10MV, STAR 2MV, Sydney, Australia Rafter Radiocarbon Laboratory, GNS Science, New Zealand Chronos 14Carbon-Cycle Facility, UNSW, Australia.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.
No. Dihexa shares a conceptual link to angiotensin IV but has different structural features. Those changes are intended to modify its behavior in biological systems.
It often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. Synonyms and CAS listings vary, so cross-checking identifiers is necessary.
Typical storage is at -20 °C in a desiccated container protected from light. Repeated freeze-thaw cycles are usually minimized to reduce degradation. Specific conditions should follow the supplier’s documentation.